507789 Stock Overview Engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Jagsonpal Pharmaceuticals Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Jagsonpal Pharmaceuticals Historical stock prices Current Share Price ₹657.80 52 Week High ₹820.05 52 Week Low ₹270.05 Beta 1.03 1 Month Change 2.75% 3 Month Change 59.66% 1 Year Change 68.52% 3 Year Change 322.34% 5 Year Change 2,396.39% Change since IPO 3,734.17%
Recent News & Updates
Jagsonpal Pharmaceuticals Limited Announces Resignation of Ashish Lakhotia as Chief Financial Officer Nov 22
Jagsonpal Pharmaceuticals Limited to Report Q2, 2025 Results on Oct 23, 2024 Oct 16
Investor sentiment improves as stock rises 16% Oct 14
Upcoming dividend of ₹5.00 per share Aug 30
Jagsonpal Pharmaceuticals Limited, Annual General Meeting, Sep 18, 2024 Aug 08
First quarter 2025 earnings released: EPS: ₹1.94 (vs ₹2.85 in 1Q 2024) Aug 08 See more updates
Jagsonpal Pharmaceuticals Limited Announces Resignation of Ashish Lakhotia as Chief Financial Officer Nov 22
Jagsonpal Pharmaceuticals Limited to Report Q2, 2025 Results on Oct 23, 2024 Oct 16
Investor sentiment improves as stock rises 16% Oct 14
Upcoming dividend of ₹5.00 per share Aug 30
Jagsonpal Pharmaceuticals Limited, Annual General Meeting, Sep 18, 2024 Aug 08
First quarter 2025 earnings released: EPS: ₹1.94 (vs ₹2.85 in 1Q 2024) Aug 08
Jagsonpal Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 07, 2024 Jul 31
Investor sentiment improves as stock rises 16% Jul 29
New minor risk - Market cap size Jun 04
Full year 2024 earnings released: EPS: ₹8.49 (vs ₹10.20 in FY 2023) May 21
Now 20% undervalued after recent price drop Mar 26
New minor risk - Market cap size Feb 05
Third quarter 2024 earnings released: EPS: ₹1.48 (vs ₹2.97 in 3Q 2023) Feb 03
Jagsonpal Pharmaceuticals Limited Announces Chief Financial Officer Changes Feb 02
Jagsonpal Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 01, 2024 Jan 26
Now 20% undervalued after recent price drop Jan 09
Now 23% undervalued after recent price drop Dec 20
Now 20% undervalued after recent price drop Nov 07
Second quarter 2024 earnings released: EPS: ₹2.84 (vs ₹3.97 in 2Q 2023) Nov 04
Jagsonpal Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 03, 2023 Oct 28
Upcoming dividend of ₹5.00 per share at 1.1% yield Aug 14
Jagsonpal Pharmaceuticals Limited, Annual General Meeting, Aug 31, 2023 Aug 06
First quarter 2024 earnings released: EPS: ₹2.85 (vs ₹0.14 in 1Q 2023) Aug 03
Jagsonpal Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 02, 2023 Jul 26
Full year 2023 earnings released: EPS: ₹10.20 (vs ₹7.48 in FY 2022) May 25
Jagsonpal Pharmaceuticals Limited Recommends Dividend for the Financial Year Ended March 31, 2023 May 24
Investor sentiment improves as stock rises 16% Apr 11
Jagsonpal Pharmaceuticals Limited Announces Appointment of Abhishek Joshi as Company Secretary and Compliance Officer Feb 14
Third quarter 2023 earnings released: EPS: ₹2.97 (vs ₹2.06 in 3Q 2022) Feb 09
Jagsonpal Pharmaceuticals Limited Announces Executive Changes Jan 01
Investor sentiment improved over the past week Dec 06
High number of new and inexperienced directors Nov 16
Second quarter 2023 earnings released: EPS: ₹3.97 (vs ₹2.79 in 2Q 2022) Nov 11
High number of new and inexperienced directors Sep 20
Jagsonpal Pharmaceuticals Limited, Annual General Meeting, Sep 14, 2022 Aug 24
First quarter 2023 earnings released: EPS: ₹0.14 (vs ₹2.61 in 1Q 2022) Aug 11
Jagsonpal Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 09, 2022 Aug 05
High number of new and inexperienced directors Jul 21
Full year 2022 earnings released: EPS: ₹748 (vs ₹6.51 in FY 2021) Jun 01
Jagsonpal Pharmaceuticals Limited to Report Q4, 2022 Results on May 30, 2022 May 24
Investor sentiment improved over the past week May 20
Investor sentiment improved over the past week Apr 06
Investor sentiment improved over the past week Mar 22
Now 21% undervalued Feb 21
Investor sentiment improved over the past week Feb 18
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Feb 13
Jagsonpal Pharmaceuticals Limited Announces Resignation of Sanjiv Kumar Dudeja as Chief Financial Officer Feb 03
Investor sentiment improved over the past week Dec 14
Upcoming dividend of ₹4.00 per share Oct 22
Second quarter 2022 earnings released: EPS ₹2.79 (vs ₹1.53 in 2Q 2021) Oct 21
Investor sentiment improved over the past week Sep 09
Investor sentiment deteriorated over the past week Aug 20
First quarter 2022 earnings released: EPS ₹2.61 (vs ₹0.96 in 1Q 2021) Aug 18
Investor sentiment improved over the past week Jul 09
Full year 2021 earnings released: EPS ₹6.51 (vs ₹3.00 in FY 2020) Jul 02
Investor sentiment improved over the past week Jun 16
Investor sentiment improved over the past week Jun 01
Investor sentiment improved over the past week Apr 20
New 90-day high: ₹93.35 Feb 17
Investor sentiment improved over the past week Feb 17
Jagsonpal Pharmaceuticals Limited to Report Q3, 2021 Results on Feb 12, 2021 Feb 04
Insider recently bought ₹1.3m worth of stock Jan 07
Investor sentiment improved over the past week Jan 04
New 90-day high: ₹80.55 Jan 01
Insider recently bought ₹393k worth of stock Dec 23
Insider recently bought ₹224k worth of stock Dec 14
Insider recently bought ₹1.0m worth of stock Dec 08
Market bids up stock over the past week Dec 07
New 90-day high: ₹72.50 Dec 07
Insider recently bought ₹506k worth of stock Dec 06
Insider recently bought ₹1.0m worth of stock Nov 22
Market bids up stock over the past week Nov 17
New 90-day high: ₹48.10 Nov 16
Second quarter 2021 earnings released: EPS ₹1.53 Nov 11
New 90-day high: ₹43.85 Oct 09
Jagsonpal Pharmaceuticals Limited to Report Q4, 2020 Results on Jul 29, 2020 Jul 26 Shareholder Returns 507789 IN Pharmaceuticals IN Market 7D -2.5% 0.8% -4.3% 1Y 68.5% 39.7% 19.1%
See full shareholder returns
Return vs Market: 507789 exceeded the Indian Market which returned 19.1% over the past year.
Price Volatility Is 507789's price volatile compared to industry and market? 507789 volatility 507789 Average Weekly Movement 9.6% Pharmaceuticals Industry Average Movement 6.0% Market Average Movement 6.2% 10% most volatile stocks in IN Market 9.0% 10% least volatile stocks in IN Market 4.1%
Stable Share Price: 507789's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: 507789's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups.
Show more Jagsonpal Pharmaceuticals Limited Fundamentals Summary How do Jagsonpal Pharmaceuticals's earnings and revenue compare to its market cap? 507789 fundamental statistics Market cap ₹17.44b Earnings (TTM ) ₹243.00m Revenue (TTM ) ₹2.27b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 507789 income statement (TTM ) Revenue ₹2.27b Cost of Revenue ₹864.72m Gross Profit ₹1.40b Other Expenses ₹1.16b Earnings ₹243.00m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 9.16 Gross Margin 61.88% Net Profit Margin 10.71% Debt/Equity Ratio 0%
How did 507789 perform over the long term?
See historical performance and comparison Dividends
0.8% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 05:39 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Jagsonpal Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
